Midatech Pharma PLC (MTP) News
Filter MTP News Items
MTP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MTP News From Around the Web
Below are the latest news stories about Midatech Pharma Plc that investors may wish to consider to help them evaluate MTP as an investment opportunity.
Midatech Pharma PLC Announces Extension of Janssen collaboration re Q-SpheraMidatech announces extension of R&D collaboration with Janssen focused on Q-Sphera technologyABINGDON, UK / ACCESSWIRE / January 17, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020.On 17 June 2021, the Company announced that, using its Q-Sphera techno |
Midatech Pharma plc (NASDAQ: MTP) Stock Forecast: Downside Of -111583.69% By 2021The trading price of Midatech Pharma plc (NASDAQ:MTP) closed higher on Monday, December 13, closing at $1.41, 6.02% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, investor! |
Midatech Pharmas IND application for a Phase 1 study of MTX110 has been cleared by the US FDAMidatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced that its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinostat complex to be administered by convection enhanced delivery in patients with recurrent glioblastoma multiforme (rGBM), has been cleared by [] |
Midatech Pharma''s IND application for a Phase 1 study of MTX110 has been cleared by the US FDA - DirectorsTalk InterviewsMidatech Pharma''s IND application for a Phase 1 study of MTX110 has been cleared by the US FDA |
Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM EffectiveAccordingly, Midatech has initiated preparations for a study start in the first half of 2022.Employing the Company's MidaSolve™ technology, MTX110 solubilises panobinostat, a histone deacetylase (HDAC) inhibitor currently used in the treatment of multiple myeloma. |
38,716 Shares in Midatech Pharma plc (NASDAQ:MTP) Purchased by Credit Suisse AGCredit Suisse AG purchased a new position in shares of Midatech Pharma plc (NASDAQ:MTP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 38,716 shares of the companys stock, valued at approximately $81,000. A number of other large investors have also recently bought and [] |
Midatech Pharma plc (NASDAQ:MTP) Short Interest Down 31.3% in NovemberMidatech Pharma plc (NASDAQ:MTP) saw a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 122,800 shares, a drop of 31.3% from the October 31st total of 178,700 shares. Based on an average daily volume of 99,200 shares, the short-interest ratio is presently 1.2 days. [] |
Midatech Pharma plc (NASDAQ:MTP) Short Interest Up 19.1% in OctoberMidatech Pharma plc (NASDAQ:MTP) saw a significant growth in short interest in the month of October. As of October 29th, there was short interest totalling 178,700 shares, a growth of 19.1% from the October 14th total of 150,000 shares. Based on an average daily trading volume, of 98,300 shares, the days-to-cover ratio is presently 1.8 [] |
Is Midatech Pharma (LON:MTPH) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |